Tri-peptide hepatitis C serine protease inhibitors

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere w...

Full description

Saved in:
Bibliographic Details
Main Authors Miao, Zhenwei, Sun, Ying, Nakajima, Suanne, Tang, Datong, Wang, Zhe, Or, Yat Sun
Format Patent
LanguageEnglish
Published 18.05.2010
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.